Brought to you by 
Ivax and Serono develop oral drug for multiple sclerosis
17 Jul 2003
Executive Summary
Ivax (branded and generic drugs) and Serono SA have agreed to develop and globally market an oral formulation of Ivax's cladribine to treat multiple sclerosis.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Ivax and Serono develop oral drug for multiple sclerosis
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice